Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction : the VICTORIA echocardiographic substudy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084040" target="_blank" >RIV/00023001:_____/23:00084040 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2836" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2836</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.2836" target="_blank" >10.1002/ejhf.2836</a>

Result language

angličtina

Original language name

Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction : the VICTORIA echocardiographic substudy

Original language description

Aim Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co-primary endpoints were changes in LV end-systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high-quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 +/- 26.8 to 56.8 +/- 30.4ml/m(2); p &lt; 0.01) and LVEF significantly increased (33.0 +/- 9.4% to 36.1 +/- 10.2%; p &lt; 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI -3.8 +/- 15.4 vs. -7.1 +/- 20.5ml/m(2); p= 0.07 and LVEF +3.2 +/- 8.0% vs. +2.4 +/- 7.6%; p= 0.31). The absolute rate per 100 patient-years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p= 0.07). Conclusions In this pre-specified echocardiographic study, significant improvements in LV structure and function occurred over 8months in both vericiguat and placebo in a high-risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat&apos;s benefit in HFrEF. [GRAPHICS] .

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European journal of heart failure

ISSN

1388-9842

e-ISSN

1879-0844

Volume of the periodical

25

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

1012-1021

UT code for WoS article

000974501600001

EID of the result in the Scopus database

2-s2.0-85153709765